{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:16:20Z","timestamp":1781795780219,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.radonc.2021.03.001","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T20:28:55Z","timestamp":1615408135000},"page":"246-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity"],"prefix":"10.1016","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-2398","authenticated-orcid":false,"given":"William G.","family":"Breen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8185-0450","authenticated-orcid":false,"given":"Elizabeth B.","family":"Jeans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8130-8327","authenticated-orcid":false,"given":"Kimberly R.","family":"Gergelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda I.","family":"Garces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3814-853X","authenticated-orcid":false,"given":"Sean S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Merrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias D.","family":"Peikert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Wigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Harmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Ellerbusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"J.","family":"John Lucido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2021.03.001_b0005","unstructured":"Non-Small Cell Lung Cancer, Version 5.2020. NCCN Clinical Practice Guidelines in Oncology 2020 [cited 2020 5\/30\/2020]; Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"key":"10.1016\/j.radonc.2021.03.001_b0010","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.03.001_b0015","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.03.001_b0020","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.adro.2019.01.002","article-title":"Long-term clinical outcomes and safety profile of SBRT for centrally located NSCLC","volume":"4","author":"Arnett","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2021.03.001_b0025","doi-asserted-by":"crossref","unstructured":"Haseltine JM, et al., Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree. Practical radiation oncology, 2016. 6(2): e27\u201333.","DOI":"10.1016\/j.prro.2015.09.012"},{"key":"10.1016\/j.radonc.2021.03.001_b0030","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijrobp.2018.08.040","article-title":"Subgroup survival analysis in stage I-II NSCLC patients with a central tumor partly treated with risk-adapted SBRT","volume":"103","author":"Stam","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.03.001_b0035","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology\/RTOG 0813 Trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.03.001_b0040","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ijrobp.2018.10.008","article-title":"Stereotactic radiation for ultra-central lung tumors: good idea, or ultra-risky?","volume":"103","author":"Palma","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.03.001_b0045","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \u201cultracentral\u201d non-small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2021.03.001_b0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2015.04.014","article-title":"Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors","volume":"89","author":"Chaudhuri","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2021.03.001_b0055","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","article-title":"SUNSET: stereotactic radiation for ultracentral non-small-cell lung cancer-a safety and efficacy trial","volume":"19","author":"Giuliani","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2021.03.001_b0060","doi-asserted-by":"crossref","first-page":"e803","DOI":"10.1016\/j.cllc.2018.06.001","article-title":"Ultracentral tumors treated with stereotactic body radiotherapy: single-institution experience","volume":"19","author":"Raman","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2021.03.001_b0065","unstructured":"Organs at risk in thoracic radiation therapy. Lung Cancer Atlases, Templates, & Tools 2020 11\/13\/2020]; Available from: https:\/\/www.nrgoncology.org\/ciro-lung."},{"key":"10.1016\/j.radonc.2021.03.001_b0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.radonc.2013.09.005","article-title":"Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer","volume":"109","author":"Guckenberger","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.03.001_b0075","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0167-9473(98)00096-6","article-title":"An application of changepoint methods in studying the effect of age on survival in breast cancer","volume":"30","author":"Contal","year":"1999","journal-title":"Comput Stat Data Anal"},{"key":"10.1016\/j.radonc.2021.03.001_b0080","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1158\/1078-0432.CCR-19-2627","article-title":"Modeling the impact of cardiopulmonary irradiation on overall survival in NRG Oncology Trial RTOG 0617","volume":"26","author":"Thor","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2021.03.001_b0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2018.10.029","article-title":"Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer","volume":"133","author":"Xue","year":"2019","journal-title":"Radiother Oncol"},{"issue":"7 Suppl 3","key":"10.1016\/j.radonc.2021.03.001_b0090","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study","volume":"2","author":"Onishi","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2021.03.001_b0095","doi-asserted-by":"crossref","unstructured":"Lindberg K, et al., The Nordic HILUS-Trial - First report of a phase II trial of SBRT of centrally located lung tumors. J Thorac Oncol, 2017; 12: S340-S340.","DOI":"10.1016\/j.jtho.2016.11.369"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814021061156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814021061156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:16:52Z","timestamp":1759123012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814021061156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":19,"alternative-id":["S0167814021061156"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2021.03.001","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2021.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}